Eric Joseph

Jay Olson

Roy Buchanan

Antonio Arce

Mick (on behalf of Roanna Ruiz)

Roanna Ruiz

Thomas Yip

Wing Yip

- Enanta Pharmaceuticals, Inc. entered into an underwriting agreement on **September 30, 2025**, for a public offering of **6,500,000 shares** of its common stock.  **[1177648_0001193125-25-226828_d81869dex11.htm:1]** **[1177648_0001193125-25-226828_d81869d8k.htm:1]** 
- The public offering price for the common stock is **$10.00 per share**.  **[1177648_0001193125-25-226828_d81869d8k.htm:1]** 
- The company granted underwriters an option, exercisable for 30 days, to purchase up to an additional **975,000 shares** of common stock.  **[1177648_0001193125-25-226828_d81869dex51.htm:0]** **[1177648_0001193125-25-226828_d81869d8k.htm:1]** 
- The expected net proceeds to Enanta from the offering are approximately **$60.6 million**, after deducting underwriting discounts and commissions and estimated offering expenses, and excluding any proceeds from the exercise of the over-allotment option.  **[1177648_0001193125-25-226828_d81869d8k.htm:1]** 
- The closing of the offering is expected to occur on **October 2, 2025**.  **[1177648_0001193125-25-226828_d81869d8k.htm:1]**

Enanta Pharmaceuticals Announces Public Offering

- Enanta Pharmaceuticals announced **positive top-line results** from its **Phase 2b RSVHR study** evaluating **Zelekapavir**, an antiviral treatment for high-risk adults with acute respiratory syncytial virus (RSV) infection.  **[1177648_2160726_0]** **[1177648_2160726_1]** 
- Zelekapavir demonstrated a **clinically meaningful benefit**, significantly shortening the duration of RSV symptoms by up to a **week faster** in the HR3 population (from 19 days to 12 days) and reducing hospitalization rates (1.7% vs. 5% for placebo).  **[1177648_2160726_1]** **[1177648_2160726_4]** **[1177648_2160726_5]** 
- The study identified **multiple potential registrational endpoints** for a Phase 3 trial and confirmed Zelekapavir's **favorable safety profile**.  **[1177648_2160726_1]** **[1177648_2160726_4]** **[1177648_2160726_6]** 
- Enanta plans to advance Zelekapavir into a **Phase 3 study** and is pursuing **partnering opportunities**, highlighting that this is the first time an RSV antiviral has shown clinically meaningful benefit in this patient group.  **[1177648_2160726_7]** **[1177648_2160726_8]**

Enanta Pharmaceuticals Announces Positive Phase 2b Results for Zelekapavir in High-Risk Adult RSV Patients

- Enanta Pharmaceuticals reported positive topline results from its **Phase 2b RSVHR study** of **zelicapavir (EDP-938)** in **186 high-risk adults** with acute Respiratory Syncytial Virus (RSV) infection.  **[1177648_2160642:0]** **[1177648_2160642:3]** **[1177648_2160642:4]** **[1177648_2160642:7]** 
- The study demonstrated a **favorable safety profile** with adverse events similar to placebo and no discontinuations due to adverse events in the zelicapavir group.  **[1177648_2160642:8]** 
- Zelicapavir treatment resulted in **faster complete symptom resolution**, including **3.0 to 7.2 days faster** across various RiiQ measures in the HR3 population, and a **2-day faster symptom resolution by PGI-S** compared to placebo.  **[1177648_2160642:9]** 
- Key clinical endpoints included a **lower hospitalization rate** (1.7% for zelicapavir vs. 5.0% for placebo) and a **robust antiviral effect**, with a **5-day shorter median time to undetectable viral load** in the HR3 population.  **[1177648_2160642:10]** **[1177648_2160642:11]** 
- These compelling results support the **advancement of zelicapavir into a Phase 3 study** for high-risk adults, identifying multiple potential registrational endpoints.  **[1177648_2160642:11]**

Enanta Pharmaceuticals announces positive Zelicapavir Phase 2b RSVHR topline results

- Enanta Pharmaceuticals announced **positive topline data** from its Phase 2b study of **zelicapavir** (formerly EDP-938) for the treatment of **respiratory syncytial virus (RSV)** in high-risk adults on **September 29, 2025**.  **[1177648_0001193125-25-221791_d65423d8k.htm:1]** 
- The study demonstrated a **statistically significant 2-day faster symptom resolution** by Patient Global Impression of Severity (PGI-S) compared to placebo in both the efficacy (p=0.0446) and HR3 populations (p=0.0465).  **[1177648_0001193125-25-221791_d65423dex991.htm:3]** **[1177648_0001193125-25-221791_d65423dex991.htm:4]** 
- Zelicapavir also showed a **lower hospitalization rate** of **1.7%** (2/115) compared to **5.0%** (3/60) for placebo, and a **robust antiviral effect** with a larger viral load decline and faster time to undetectable viral load.  **[1177648_0001193125-25-221791_d65423dex991.htm:3]** **[1177648_0001193125-25-221791_d65423dex991.htm:4]** 
- The drug was **well-tolerated**, exhibiting a **favorable safety profile** with adverse events similar to placebo, and no treatment discontinuations or study withdrawals due to adverse events in the zelicapavir group.  **[1177648_0001193125-25-221791_d65423dex991.htm:2]** **[1177648_0001193125-25-221791_d65423dex991.htm:4]** 
- These compelling results **support the advancement of zelicapavir into a Phase 3 study** for high-risk adults.  **[1177648_0001193125-25-221791_d65423dex991.htm:4]**

Enanta Pharmaceuticals Announces Positive Phase 2b Zelicapavir Results for RSV

- Enanta Pharmaceuticals, Inc. announced **positive topline data** from its Phase 2b study of zelicapavir for the treatment of Respiratory Syncytial Virus (RSV) in high-risk adults.  **[1177648_0001193125-25-221527_d16388dex991.htm:0]** **[1177648_0001193125-25-221527_d16388d8k.htm:1]** 
- The study showed a **6.7-day improvement** in time to complete resolution of all RSV symptoms for patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or age ≥ 75.  **[1177648_0001193125-25-221527_d16388dex991.htm:0]** **[1177648_0001193125-25-221527_d16388d8k.htm:2]** **[1177648_0001193125-25-221527_d16388dex991.htm:2]** 
- Zelicapavir treatment resulted in a **lower hospitalization rate of 1.7%** compared to 5.0% for placebo, and a **statistically significant 2-day faster improvement** in Patient Global Impression of Severity (PGI-S) score.  **[1177648_0001193125-25-221527_d16388dex991.htm:0]** **[1177648_0001193125-25-221527_d16388dex991.htm:2]** **[1177648_0001193125-25-221527_d16388d8k.htm:3]** 
- The drug also demonstrated a **favorable safety profile** and a **4- to 5-day faster median time to undetectable viral load** compared to placebo.  **[1177648_0001193125-25-221527_d16388dex991.htm:0]** **[1177648_0001193125-25-221527_d16388dex991.htm:2]** **[1177648_0001193125-25-221527_d16388d8k.htm:3]**

ENANTA PHARMACEUTICALS (ENTA)